Go Deep
Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,769 | 35.0 | 2.60 | 0.37 | 63.36 |
| Oct 2026 | 22,770 | 35.0 | 2.60 | 0.37 | 63.43 |
| Oct 2026 | 22,633 | 36.0 | 2.67 | 0.37 | 65.24 |
| Oct 2026 | 22,647 | 35.7 | 2.64 | 0.37 | 64.48 |
| Oct 2026 | 22,981 | 35.6 | 2.46 | 0.37 | 59.91 |
| Oct 2026 | 22,965 | 33.3 | 2.47 | 0.37 | 60.44 |
| Oct 2026 | 23,119 | 32.7 | 2.28 | 0.37 | 59.44 |
| Oct 2026 | 23,352 | 34.0 | 2.21 | 0.37 | 57.78 |
Sino Biopharmaceutical Limited Quarterly Results
Quarterly data isn't available for this company right now.
Sino Biopharmaceutical Limited Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 31,834,488,000.0 | 28,866,159,000.0 | 26,199,409,000.0 | 26,026,164,000.0 | — |
| Net Profit | 2,343,348,000.0 | 3,499,834,000.0 | 2,331,939,000.0 | 2,543,570,000.0 | — |
| EPS | 0.1 | — | 0.1 | 0.1 | 0.8 |
Sino Biopharmaceutical Limited Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 76,009,821,000.0 | 65,408,069,000.0 | 63,604,819,000.0 | 64,064,284,000.0 | — |
| Total Liabilities | 33,923,894,000.0 | 22,633,999,000.0 | 25,434,866,000.0 | 26,120,736,000.0 | — |
| Total Equity | 30,670,958,000.0 | 31,960,789,000.0 | 30,474,469,000.0 | 29,747,035,000.0 | — |
Owes vs Owns
Sino Biopharmaceutical Limited owed ¥0.45 for every ¥1 it owned in Dec 2025, up from ¥0.41 in Dec 2022.
| Period | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Owes vs Owns | 0.45× | 0.35× | 0.40× | 0.41× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sino Biopharmaceutical Limited Assets & Liabilities Breakdown (CNY millions)
What it owns — Dec 2025
Cash & short-term investments 30.2%Receivables 7.5%Inventory 3.0%Fixed assets (tangible) 13.5%Intangible assets 9.3%Long-term investments 2.2%Other assets 34.4%
How it's funded — Dec 2025
Short-term debt 11.0%Long-term debt 10.0%Payables 2.0%Other liabilities 21.6%Shareholders' equity 55.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 22,961.5 | 14,817.9 | 14,118.2 | 16,921.7 |
| Receivables | 5,700.9 | 4,310.8 | 3,803.8 | 3,722.2 |
| Inventory | 2,256.7 | 2,373.1 | 1,993.5 | 2,328.8 |
| Fixed assets (tangible) | 10,233.4 | 10,288.2 | 9,912.2 | 9,251.2 |
| Intangible assets | 7,052.2 | 3,061.0 | 2,909.0 | 1,914.5 |
| Long-term investments | 1,637.1 | 1,620.1 | 12,243.7 | 13,198.2 |
| Other assets | 26,168.1 | 28,937.0 | 18,624.5 | 16,727.8 |
| Liabilities & equity | ||||
| Short-term debt | 8,395.4 | 7,602.1 | 11,135.9 | 9,663.4 |
| Long-term debt | 7,584.0 | 1,996.8 | 1,074.4 | 3,933.9 |
| Payables | 1,497.3 | 1,497.5 | 1,334.7 | 1,637.4 |
| Other liabilities | 16,447.2 | 11,537.7 | 11,889.8 | 10,886.1 |
| Shareholders' equity | 42,085.9 | 42,774.1 | 38,170.0 | 37,943.5 |
| Net tangible assets | 23,618.8 | 28,899.8 | 27,565.5 | 27,832.6 |
Sino Biopharmaceutical Limited Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | 9,291,821,000.0 | 6,615,120,000.0 | 6,065,734,000.0 | 6,265,155,000.0 |
| Investing Activities | -12,413,758,000.0 | -1,709,126,000.0 | -756,975,000.0 | -4,070,819,000.0 |
| Financing Activities | 4,157,238,000.0 | -6,315,086,000.0 | -6,548,990,000.0 | -3,186,390,000.0 |